Thank you, Juan. So, looking at slide eight and the financials, in addition to what you have already said, I have just a few points. On the cost side, we obviously have an elevated level. A lot of that is driven by the goodwill impairment in Germany as well as other items affecting comparability. Those other items total around 150 million during the quarter, and it is very much related to the acceleration of the operational excellence programme we are doing on an underlying basis.
The costs are developing slightly ahead of plan, given the fact that we've had a consolidation of the Savoy portfolio, which increases the cost base for 2026 by about 300 million, which would take our cost target for the year to around 12 billion. Right now, we're trending slightly below that, and we expect to end the year below the 12 billion level.
On the net financial expense, it is now coming down on an underlying basis. If you look at the cash component of it. And that is obviously driven by the capital raise and the asset sale, which reduces the debt level. So we are seeing a positive impact there. That positive impact should be a bit larger going forward as the liquidity management in the quarter hasn't been optimal due to the fact that we've done tenders and bought back bonds. So we've had to hold more liquidity on deposit accounts rather than fully using the capital to reduce the debt. So we should see further tailwinds on the cash component of the net financial expense in Q4 and onwards, marginally offset with the higher interest rates, which is only affecting our RCF and not the other debt, as the other debt is on a fixed coupon basis. And then you can see that there have been a few one-offs on the net financial expense, mainly related to the bond buybacks that we did for '27 that were bought back above 100. So there is a negative effect there. We also paid the consent fee to the RCF holders. When we did the asset sale, which also has a negative effect.
Moving to the next page, which is on the servicing income, Juan has gone through most of the items here with the negative development on the external income. But at the same time, we have had good cost control, which means that the margin is stable in terms of the 12-month outlook. But year on year, we see an improvement of the margin, going from 22% to 24% this quarter. Moving to the investing P&L, there is a pretty large decrease if you look at the adjusted EBIT. And that is very much related to the consolidation of Savoy, which typically seasonally has a very weak Q3. The cost level in Savoy is just over 100 million in Q3 with income being less than that. So there is actually a negative contribution for Savoy that typically changes quite a bit in Q4, where Savoy has its seasonally strongest quarter, and we expect the cost level to be approximately the same in Q4, but with income and collections more than doubling. So the negative effect we have in Q3 from this consolidation will reverse in Q4 and become a positive effect instead. And here we should also mention that the EBIT is stronger compared to last year, very much related to the asset sale of the portfolio. That led to a capital gain of about 430 million on the portfolio investments that you mentioned, which is 617 million in the quarter. We think the outlook looks pretty good for Q4, and we expect to be able to be above that level with similar levels of returns in the next quarter, which is going to be dependent on one or two deals that could be binary. But assuming that everything goes according to plan, we expect to be able to improve volumes further. On the cost development shown on the next slide, we have seen a positive trend over the past couple of years, with personnel expenses coming down by 20% and other costs by 14%. We are obviously continuing to work on this. We expect this development to continue and accelerate slightly in 2027 compared to the development we have seen in 2026. You can already see in the Q3 numbers that there is a slightly larger decline of the FTE base in Q3 versus what we have seen in the last couple of quarters. That should accelerate further going forward. And this has led to some restructuring costs that we've taken in Q3, and we expect these costs to be clearly higher in Q4, which will enable us to transform the business faster. And again, we will come back with further details, but the plan is to approach approximately 1.1 billion in total costs in 2027.
To summarize the quarter, the main priority for us as a company is to deliver. We are doing that right now. Obviously help with the capital raise and the asset sale. But going forward, the deleveraging will be fully driven by organic development. And we've had this large goodwill impairment in Germany. And we are delivering the operational excellence programme. On the servicing side. We continue to see, unfortunately, the negative external income development, mainly driven by the UK and Germany, but we are able to offset that by reducing the cost level and therefore keeping the margin largely flat. On the investing side, we see an acceleration of investments. We expect that acceleration to continue. For now, returns are still stable at high levels. We expect returns to come down, but still be at sufficiently good levels for us to do these investments. With that, we will stop and open up for Q&A.